###### Strengths and limitations of this study

-   This is a nationwide study comparing early and long-term opioid use among patients with low back pain (LBP) who seek initial care from conservative therapists, physician specialists and primary care physicians.

-   We go beyond investigating the odds of opioid use for a one-time LBP event, by examining associations with both early and long-term opioid use among patients with new-onset LBP.

-   We provide a broader depiction of conservative therapy than prior studies, as we included chiropractors and acupuncturists, as well as other MD specialists.

-   This study assesses the impact of state regulations of access to physical therapy on choice of initial provider.

-   This is a claims-based study; therefore, causation cannot be inferred, and different patient characteristics we could assess are limited.

Introduction {#s1}
============

Over the past decade, there has been an increase in opioid use in the USA, with over 12 million Americans reporting long-term opioid use or misuse in 2015.[@R1] The National Survey on Drug Use and Health reported over 42 000 prescription opioid-related deaths in 2016, with total estimated costs of prescription opioid use reaching US \$78.5 billion.[@R4] One of the most common conditions for which opioids are prescribed is low back pain (LBP).[@R2] Several studies have reported that opioids are the most frequently prescribed medication for treatment of LBP,[@R4] and more than half of opioid users report having a history of back pain.[@R6] This frequency of opioid prescribing is particularly concerning given that LBP is one of the three most common conditions for which Americans seek medical care.[@R2]

Given the high prevalence of LBP, several guidelines have been issued for treatment, and specifically discourage opioids to treat pain. The American College of Physicians and the Centers for Disease Control recommend non-pharmacological treatments including exercise, physical therapy (PT), spinal manipulation, acupuncture and massage.[@R2] These guidelines indicate that opioids should not be considered as a treatment option for LBP unless recommended treatments fail and if the benefits of their use outweigh the risk for the individual patient.[@R2] Prior to the release of these recommendations, physician visits for new-onset LBP were much more common than non-pharmacological therapies like chiropractic care, PT and acupuncture.[@R8]

Several studies have attempted to elucidate the predictors of opioid use among patients with LBP. Comparisons of the treatment patterns of primary care physicians (PCPs) and conservative therapists (defined as chiropractors, physical therapists, acupuncturists) suggest that the use of conservative therapies for LBP may decrease the likelihood of opioid use.[@R9] Despite these findings, there has been little research comparing early and long-term opioid use among patients seeking initial care from various providers, including PCPs, chiropractors, physical therapists and acupuncturists as well as patients seeing orthopaedic surgeons, neurosurgeons and emergency physicians.[@R12] The purpose of this study is to examine the association of type of initial provider with subsequent early and long-term opioid use in a national sample of patients with new-onset LBP whose treatment could reasonably be managed by non-pharmacological therapy.

Methods {#s2}
=======

Study sample {#s2-1}
------------

We conducted a retrospective study of patients seen by a healthcare provider for new-onset LBP management and who were opioid-naïve at the time of the initial visit. We used de-identified administrative claims data from the OptumLabs Data Warehouse, which includes medical and pharmacy claims, laboratory results and enrolment records for commercial and Medicare Advantage (MA) enrollees. The database contains longitudinal health information on enrollees and patients, representing a diverse mixture of ages, ethnicities and geographical regions across the USA.

The various health plans individuals were enrolled in all provide comprehensive insurance coverage for physician, hospital, and prescription drug services.

The index episode of LBP was identified using claims from 2008 to 2013 with additional claims data covering 2006--2015 to ascertain pre-index visit opioid use and low back conditions and to allow a follow-up period. Patients needed to be continuously enrolled for at least 24 months both before and following the index date (total 48 months) with both medical and pharmacy claims data available during that period. The study sample included adults aged 18 years or older with a new outpatient diagnosis of LBP who had commercial or MA insurance.

To qualify, LBP diagnosis appeared in the first location on a patient's index date insurance claim. New-onset LBP was defined as no diagnosis of LBP or back procedures, including spinal surgery, spinal injections and spinal nerve stimulators during the 12-month period prior to the index event ([figure 1](#F1){ref-type="fig"}). Given the heterogeneity of claims data in a commercial insured population, we constructed our inclusion and exclusion criteria with the specific purpose of maximising the likelihood that our analytic sample comprised our target population.

![Inclusion and exclusion criteria. Initially, 8 797 787 patients with LBP were identified. Patients with an insufficient clean period (LBP within the last 1 year), patients with a diagnosis of LBP that was not in the first position of their diagnosis and LBP in only inpatient settings were excluded, reducing the number of patients to 4 263 713. Patients were excluded if they were not continuously enrolled in their insurance for 24 months before and after the initial LBP visit and if they were aged \<18 years, reducing the number of patients to 422 871. Patients with exclusionary conditions, LBP that was not limited to the low back, patients with back procedures in the 12 months prior to the index LBP visit and patients with any opioid use in the 12 months before the index visit were excluded, leaving 216 504 patients in our sample.](bmjopen-2018-028633f01){#F1}

Exclusion criteria {#s2-2}
------------------

Patients were excluded if they had 1) a prescription for opioids in the 12 months prior to the index event (see [online supplementary appendix 1a](#SP1){ref-type="supplementary-material"} for a list of opioids included), 2) a diagnosis of neoplasia in this 12-month period or within a 3-month period after the index LBP event or 3) a LBP-related diagnoses that would typically not be amenable to conservative therapy in the 3 months on or following the index date (see [online supplementary appendix 1b--d](#SP1){ref-type="supplementary-material"} for International Classification of Diseases, Ninth Revision (ICD-9) and Current Procedural Terminology (CPT) codes for inclusion/exclusion criteria). Each patient was only included in the study once.
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Dependent variables {#s2-3}
-------------------

Early opioid use was defined as an opioid fill within 30 days of the index visit. Long-term use was defined as an initial opioid fill within 60 days of the index date and either 120 or more days' supply of opioids over 12 months, or 90 days or more supply of opioids and 10 or more opioid prescriptions over 12 months. This definition relied on previous literature.[@R6]

Independent variables {#s2-4}
---------------------

### Patient characteristics {#s2-4-1}

We identified patient characteristics and comorbidities using ICD-9 codes for the claims data in the 2 years prior to the index event. Characteristics included age, sex/gender, race/ethnicity, insurance (commercial or MA) and state of residence (which was mapped to one of four US census regions: Northeast, South, Midwest and West). Race and ethnicity are defined as black, Hispanic, Asian or white ([table 1](#T1){ref-type="table"}). Sex/gender is determined based on enrolment records. Ethnicity was assigned by an external vendor based on a structured, rule-based system that combines analysis of first names, middle names, surnames and surname prefixes and suffixes, with geographic reference files. Values were then categorised to comply with data de-identification requirements. Physical comorbidities were assessed using a modification of the Elixhauser index[@R15] in which mental health conditions were excluded. Other comorbidities, listed in [table 2](#T2){ref-type="table"}, included eight mental health conditions and a condition comprising chronic pain, fibromyalgia and fatigue. The latter conditions were included based on prior studies that have reported an association between such conditions and opioid use[@R16] and their specifications were based on the Centers for Medicare and Medicaid Services Chronic Conditions Data Warehouse.[@R18]

###### 

Patient characteristics

                           Entry-point provider                                                                                                                                                          
  ------------------------ ---------------------- --------------- ------------------- ------------------ ---------------- ------------------- ------------------- ------------------ ------------------- -----------------
  Full sample---N (%)      216 504 (100)          50 014 (23.1)   3499 (1.6)          1839 (0.8)         114 782 (53.0)   9335 (4.3)          8746 (4.0)          4422 (2.0)         3246 (1.5)          578 (0.3)
  Age, year---mean (SD)    48.1 (15.9)            45.7 (14.9)     47.0 (15.7)         42.4 (10.6)        47.7 (15.4)      50.1 (16.4)         50.1 (18.3)         51.3 (15.3)        46.9 (15.0)         52.2 (14.8)
  Sex/gender---N (%)                                                                                                                                                                                     
   Female                  108 347 (50.1)         22 808 (45.6)   1995 (57.1)         972 (52.9)         58 182 (50.7)    4648 (49.8)         4560 (52.2)         2282 (51.6)        1554 (47.9)         245 (42.4)
   Male                    107 660 (49.8)         27 193 (54.4)   \>1493 (\>42.6)\*   \>856 (\>46.5)\*   56 517 (49.2)    4674 (50.1)         \>4175 (\>47.7)\*   2140 (48.4)        \>1681 (\>51.8)\*   333 (57.6)
  Race/ethnicity---N (%)                                                                                                                                                                                 
   Black                   18 907 (8.7)           2190 (4.4)      191 (5.5)           45 (2.4)           11 755 (10.2)    802 (8.6)           1192 (13.6)         494 (11.2)         208 (6.4)           50 (8.7)
   Hispanic                20 936 (9.7)           3766 (7.5)      263 (7.5)           224 (12.2)         12 212 (10.6)    752 (8.1)           860 (9.8)           541 (12.2)         293 (9.0)           38 (6.6)
   Asian                   9344 (4.3)             1636 (3.3)      224 (6.4)           747 (40.6)         4885 (4.3)       354 (3.8)           270 (3.1)           194 (4.4)          218 (6.7)           15 (2.6)
   White                   159 503 (73.7)         40 709 (81.4)   2666 (76.2)         732 (39.8)         81 971 (71.4)    7046 (75.5)         6115 (69.9)         3013 (68.1)        2394 (73.8)         449 (77.7)
   Unknown (missing)       7814 (3.6)             1713 (3.4)      155 (4.4)           91 (4.9)           3959 (3.4)       381 (4.1)           309 (3.5)           180 (4.1)          133 (4.1)           26 (4.5)
  Insurance---N (%)                                                                                                                                                                                      
   Commercial              183 117 (84.7)         44 520 (89.0)   3048 (87.1)         1827 (99.3)        99 842 (87.0)    7696 (82.5)         6236 (71.3)         3601 (81.4)        2891 (89.1)         472 (81.7)
   Medicare Advantage      32 937 (15.2)          5476 (11.0)     \>440 (\>12.6)\*    12 (0.7)           14 900 (13.0)    \>1628 (\>17.4)\*   \>2499 (\>28.6)\*   \>810 (\>18.3)\*   \>344 (\>10.6)\*    \>95 (\>16.4)\*

Age, sex/gender, race/ethnicity and insurance are all statistically significant at p\<0.0001.

\*Cell suppressed due to small N's with unknown sex/gender or insurance in the corresponding column. Two additional initial type of providers---other non-MD (eg, physician assistants, advance practice nurses) and radiologist---were included in the analyses but not reported in this table. Outcomes with a sample size \<11 are not shown due to small sample size. There were a small number of individuals with unknown sex/gender and insurance type, and if we provided exact n's, readers may be able to infer the unknown n's which would be problematic since we cannot disclose n\<11 for purposes of confidentiality of the data. For example, in [table 1](#T1){ref-type="table"} under male PT, \>1493 means that there was an unknown sex/gender row or column with n\<11. Therefore, the number of male PT first individuals is between 1493 and 1504.

PT, physical therapy.

###### 

Odds of early and long-term opioid use by initial provider

                                                                                             Early use, OR (95% CI)   Long-term, OR (95% CI)
  -------------------------------------------- --------------------------------------------- ------------------------ ------------------------
  Initial provider                             PT (n=3499)                                   0.15 (0.13 to 0.17)      0.27 (0.15 to 0.48)
  DC (n=50 014)                                0.10 (0.09 to 0.10)                           0.22 (0.18 to 0.26)      
  Acupuncture (n=1839)                         0.09 (0.07 to 0.12)                           0.07 (0.01 to 0.48)      
  Ortho (n=9335)                               0.63 (0.60 to 0.67)                           1.10 (0.92 to 1.30)      
  Emerg Med (n=8746)                           2.66 (2.54 to 2.78)                           0.92 (0.77 to 1.10)      
  Neurosgn (n=578)                             0.58 (0.47 to 0.71)                           1.50 (0.88 to 2.58)      
  MD other (n=4422)                            0.50 (0.46 to 0.54)                           2.03 (1.70 to 2.41)      
  Rehab (n=3246)                               0.54 (0.49 to 0.59)                           1.78 (1.40 to 2.26)      
  Age (years)                                  45--64 vs 18--44                              1.07 (1.05 to 1.10)      1.32 (1.19 to 1.46)
  65--74 vs 18--44                             0.89 (0.82 to 0.97)                           0.79 (0.54 to 1.15)      
  75+ vs 18--44                                0.80 (0.72 to 0.89)                           0.67 (0.45 to 1.00)      
  Sex/gender                                   Female vs male                                0.83 (0.81 to 0.85)      0.82 (0.76 to 0.89)
  Race                                         Asian vs white                                0.49 (0.46 to 0.52)      0.29 (0.20 to 0.42)
  Black vs white                               0.90 (0.87 to 0.94)                           0.87 (0.76 to 0.99)      
  Hispanic vs white                            0.79 (0.76 to 0.82)                           0.69 (0.59 to 0.81)      
  Unknown vs white                             0.84 (0.79 to 0.89)                           0.65 (0.51 to 0.83)      
  Region                                       Midwest vs Northeast                          0.78 (0.75 to 0.81)      0.74 (0.64 to 0.87)
  South vs Northeast                           1.11 (1.08 to 1.14)                           1.22 (1.11 to 1.34)      
  West vs Northeast                            1.01 (0.97 to 1.04)                           1.17 (1.02 to 1.34)      
  Insurance type                               Medicare \<65 years vs commercial insurance   0.98 (0.89 to 1.08)      3.77 (3.19 to 4.46)
  Medicare ≥65 years vs commercial insurance   0.98 (0.89 to 1.08)                           2.24 (1.54 to 3.26)      
  Comorbidities                                Anxiety                                       1.05 (1.01 to 1.09)      1.46 (1.30 to 1.63)
  Bipolar disorder                             1.11 (1.01 to 1.21)                           1.41 (1.13 to 1.76)      
  Depression                                   1.11 (1.07 to 1.15)                           1.55 (1.39 to 1.73)      
  Dementia                                     0.80 (0.70 to 0.92)                           0.99 (0.73 to 1.36)      
  ADHD                                         0.87 (0.80 to 0.95)                           1.00 (0.75 to 1.32)      
  Alcohol use disorder                         1.08 (0.98 to 1.20)                           1.28 (0.98 to 1.66)      
  Substance use disorder                       1.06 (0.93 to 1.22)                           2.34 (1.76 to 3.10)      
  Fibromyalgia/chronic pain/fatigue            0.96 (0.92 to 1.01)                           1.92 (1.71 to 2.16)      
  PTSD                                         0.84 (0.69 to 1.03)                           1.16 (0.77 to 1.77)      
  Psychotic disorder                           0.86 (0.74 to 0.99)                           0.76 (0.55 to 1.05)      
  Elixhauser physical                          1.07 (1.06 to 1.08)                           1.24 (1.21 to 1.27)      

The following variables were all included in the regression: age, sex/gender, race/ethnicity, insurance, Elixhauser, which included physical comorbidities and mental health comorbidities. PCP is the reference group (n=114 782); adjusted for race/ethnicity, sex/gender, region and insurance type. Two additional initial providers---other non-MD (eg, physician assistants, advance practice nurses) and radiologist---were included in the analyses but not reported in this table.

\*P\<0.01.

ADHD, attention deficit hyperactivity disorder; DC, chiropractor; Emerg Med, emergency medicine physician; MD other, other physician; Neurosgn, neurosurgeon; Ortho, orthopaedic surgeon; PCP, primary care physician; PT, physical therapy; PTSD, post-traumatic stress disorder; Rehab, rehab physician.

Based on the index claim date of patients with an eligible LBP diagnosis, initial providers were characterised as physical therapist, chiropractor, acupuncturist, PCP, orthopaedic surgeon, emergency medicine physician, neurosurgeon, radiologists, other non-physicians (physician assistant or nurse practitioners) or physical medicine and rehabilitation physician according to provider specialty and procedure codes. If a patient saw both a physician and a conservative therapist on the index date, the initial provider was assumed to be the physician, although this was notably a small number of individuals (n=262).

Patient access to PT in every state was classified as either 'limited', 'provisional' or 'unrestricted', based on the three levels of patient access outlined by the American Physical Therapy Association.[@R19] To access PT for their initial LBP visit in limited access states, patients must have a prior relevant medical diagnosis, a recent diagnosis from a physician or other specified clinician, and/or a prior physician referral to PT. States with provisional access permitted patients to see physical therapists with some provisions that vary by state. Restrictions in provisional access states include time and/or visit limits and physician referrals for specific interventions. Patients in unrestricted states do not face these restrictions when seeking initial care from a physical therapist. There were 6 states with limited access to PT, 26 states with provisional access and 18 states with unrestricted access to PT.[@R19]

Statistical analyses {#s2-5}
--------------------

The main analyses included multivariable logistic regressions with early opioid use and long-term opioid use as outcomes and entry-point provider as the main independent variable. The reference group for these comparisons was patients who visited PCP first for the LBP. All models were adjusted for age, sex/gender, race/ethnicity, geographic region, insurance type, the Elixhauser physical index as a continuous count of physical comorbidities and, individually, mental health comorbidities.

As a supplemental alternative to adjusting for baseline confounding through regression adjustment, we invoked two-to-one propensity score matching (two PCP: one physical therapist or two PCP: one chiropractor) without replacement to achieve baseline covariate balance among patients who initially saw chiropractor first, saw a physical therapist first or who saw PCP first.[@R20] The propensity scores were calculated as predicted probabilities of chiropractor first and a physical therapist first as opposed to PCP first as a function of the following matching variables: age, sex/gender, race/ethnicity, baseline comorbidities, geographic region, calendar year of the index visit, copay, deductible, plan type, history of pregnancy within 12 months, history of vehicular accidents within 12 months, history of opioid use within the year prior to the opioid-free period, LBP diagnoses in the 13--24 months prior to the index visit and prior PT visits. The propensity score for PT also considered the state PT access category, but the chiropractor propensity score did not. We examined the covariate balance in the matched samples through the standardised mean differences of each covariate. Finally, we applied a logistic model using the matched sample to assess the association between chiropractor compared with PCP as the initial provider seen and PT compared with PCP as the initial provider seen with the outcomes early term opioid use and separately long-term opioid use (binary variables). The calliper for propensity matching was set to 0.001 for both PT and chiropractor models.

In stage 1 of the propensity analysis, multivariable odds of initial chiropractic care and initial physical therapist versus initial PCP as a function of baseline covariates were measured. Covariates measured include age, sex/gender, race, geographic region, all mental and physical comorbidities included in the previous models, pregnancy and motor vehicle accidents in the 12 months prior to the LBP visit, opioid use in the 13--24 months prior to the LBP index visit, PT, chiropractic care and acupuncture in the 24 months prior to the LBP visit and year of index visit. PT state access was only used for the PT vs PCP propensity analysis.

For all logistic models, we calculated adjusted ORs with 95% Wald CIs. We also evaluated overall model fit, model discrimination (C-statistic) and calibration (Hosmer-Lemeshow test) for all logistic models ([online supplementary appendix 2](#SP2){ref-type="supplementary-material"}). While the Hosmer-Lemeshow models were significant, this was likely due to the large sample sizes used for this study. The differences between the observed and expected values within the decile groups was relatively small suggesting credible calibration of the models and statistical significance due to the large sample sizes.[@R22] We further validated the covariate-adjusted ORs of early use and long-term use as a function of initial provider using the bootstrap method.[@R24] The resampling rate was 200 with a two-third/one-third sampling ratio. The bootstrapped estimates were then used to construct means and 95% CIs for the ORs.
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Patient and public involvement {#s2-6}
------------------------------

No patient involvement.

Results {#s3}
=======

A total of 8 797 787 patients had a visit with a provider for LBP during the study period, and 216 504 met all inclusion/exclusion criteria ([figure 1](#F1){ref-type="fig"}). More than half the patients initially saw a PCP (n=114 782, 53.0%), and the most frequent initial conservative provider seen was chiropractor (50 041, 23.1%) followed by physical therapist 3499 (1.6%) and acupuncturist 1839 (0.8%). Patient demographics by initial provider are shown in [table 1](#T1){ref-type="table"}. Most patients had commercial insurance (183 117, 84.7%); the remainder had MA coverage. Of patients with an acupuncturist as the initial provider type, nearly all (99.3%) had commercial insurance. For all other initial provider types, 87%--89% of patients had commercial insurance. Approximately 18% of patients received an opioid fill within 3 days of the initial LBP visit, 22% received such a fill within the first 30 days and 1.2% met criteria for long-term use. Eighteen per cent of patients received short-acting opioids (eg, oxycodone, hydrocodone, codeine); 17.4% received prescriptions for non-steroidal anti-inflammatory drugs. The choice of initial provider varied by state PT access category. For example, in limited access states, 55.2% of initial providers were PCP, 0.9% were physical therapists and 25.7% were chiropractors. In provisional access states, the rates were 51.7% for PCPs, 1.6% for physical therapists and 23.2% for chiropractors, and in unrestricted access states, the rates were 55.8% for PCPs, 2.6% for physical therapists, and 22.6% for chiropractors.

Initial provider was associated with early and long-term opioid use outcomes in the adjusted multivariate models ([table 2](#T2){ref-type="table"}). Compared with seeing a PCP as initial provider, patients who first saw conservative therapists (chiropractor, acupuncturists and physical therapists) all had significantly decreased odds of both early and long-term opioid use. For early opioid use, patients initially visiting chiropractors had 90% decreased odds (95% CI 0.09 to 0.10) while those visiting an acupuncturists had 91% decreased odds (95% CI 0.07 to 0.12) and those visiting physical therapists had 85% decreased odds (95% CI 0.13 to 0.17). Chiropractors, acupuncturists and physical therapists all had major decreased odds of long-term opioid use compared with those who initially saw PCPs (0.22, 95% CI 0.18 to 0.26; 0.07, 95% CI 0.01 to 0.48; 0.27, 95% CI 0.15 to 0.48, respectively). Compared with PCPs, orthopaedic surgeons, neurosurgeons and rehab physicians as initial providers decreased patients' odds of early opioid use (0.63, 95% CI 0.60 to 0.67; 0.58, 95% CI 0.47 to 0.71; 0.54, 95% CI 0.49 to 0.59, respectively), while patients seeing emergency physicians initially had significantly increased odds of early opioid use (2.66, 95% CI 2.54 to 2.78). However, compared with PCP as first provider, odds for long-term opioid use were no longer significantly different for orthopaedic surgeons, neurosurgeons and emergency physicians (1.10, 95% CI 0.92 to 1.30; 1.50, 95% CI 0.88 to 2.58; 0.92, 95% CI 0.77 to 1.10, respectively), but were significantly increased for rehab physicians (1.78, 95% CI 1.40 to 2.26). ([table 2](#T2){ref-type="table"}). The estimates reported using bootstrapping methods indicated little or no differences with the actual results ([online supplementary appendix 3 and 4](#SP3 SP4){ref-type="supplementary-material"}).

Patients with anxiety, bipolar disorder and depression had significantly increased odds of long-term opioid use, as did those diagnosed with drug use disorders and fibromyalgia/chronic pain/fatigue ([table 2](#T2){ref-type="table"}).

Propensity score matched odds of long-term opioid use were significantly lower for chiropractic care first compared with PCP first and for PT first as compared with PCP first with ORs consistent with findings in our primary covariate-adjusted logistic models (detailed results presented in [online supplementary appendix 5](#SP5){ref-type="supplementary-material"}).
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Multivariable odds of initial chiropractic care and initial PT versus initial PCP as a function of baseline covariates {#s3-1}
----------------------------------------------------------------------------------------------------------------------

Patients in states with provisional access to PT had 1.21 (95% CI 1.05 to 1.40) times the odds of seeing a physical therapist initially while patients in states with unrestricted access to PT had 1.67 (95% CI 1.41 to 1.98) times the odds of seeing a physical therapist initially all compared with patients in states with limited PT access ([online supplementary appendix 6](#SP6){ref-type="supplementary-material"}).
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Discussion {#s4}
==========

Initial treatment from conservative therapists in those with LBP was associated with a marked decrease in the odds of early and long-term opioid use. To our knowledge, this is one of the first national studies to compare early and long-term opioid use among patients with LBP who receive care from conservative therapists, physician specialists and PCPs. Although the impact of unmeasured confounders cannot be ruled out in this retrospective observational cohort study, the findings warrant careful consideration.

Several factors may help explain the apparent protective effect of conservative therapists. Since non-physicians are unable to prescribe opioids, patients seeking conservative therapy do not receive opioid prescriptions at the index visit, and subsequent visits to an MD would be required to obtain such prescriptions. There may be selection bias among patients choosing to seek initial treatment from conservative therapists, and such biases could be related to educational level or preferences which may also result in decreased desire for those patients to use opioids. Additionally, the conservative therapy provided may result in decreased pain and improved back-related function so that patients do not need or seek opioid medications. A growing body of evidence suggest that spinal manipulation, massage, acupuncture and superficial heat are effective for reducing acute LBP intensity and improving function.[@R23] The conservative therapists studied in this analysis can incorporate one or more of these approaches: physical therapist (manipulation, massage, heat), chiropractor (manipulation, massage, heat) and acupuncturist (acupuncture, massage).[@R23] Therefore and importantly, early engagement of conservative therapists may decrease initial opioid prescriptions in association with MD visits by providing the opportunity to incorporate evidence-based non-pharmacological interventions.

Notably, state access to PT had a considerable association with choice of initial provider. Compared with states with limited access to PT, patients in states with unrestricted and provisional access had 67% and 21% higher odds of visiting physical therapists initially, respectively. Given that initial PT is associated with significant reductions in early and long-term opioid use, these observations are potentially important.

The discrepancy between early and long-term use among PCPs and physicians specialists is also interesting. While patients who initially see orthopaedic surgeons, neurosurgeons, rehabilitation physicians and other physicians have significantly lower odds of early opioid use compared with PCPs, patients who initially see these physicians have similar or increased odds of long-term opioid use compared with PCPs. While we do not have a measure of pain severity, we hypothesise that physician specialists are trying to avoid prescribing opioids at the index visit, but if patients return at follow-up due to persistent pain, physicians are likely to prescribe opioids.

Comparisons to prior studies {#s4-1}
----------------------------

Our results are consistent with prior studies showing high rates of opioid prescription fills for patients with LBP who were seen by emergency department physicians.[@R3] While there are very few studies suggesting that PT and chiropractic care are used in emergency departments in the USA,[@R27] other countries have successfully introduced physical therapists into emergency departments to treat patients with LBP.[@R27]

Certain comorbidities were also associated with increased odds of opioid use. Patients with fibromyalgia, chronic pain and fatigue and those with certain psychiatric conditions, including anxiety, bipolar disorder and depression had greater odds of long-term opioid use than patients without these disorders. This is consistent with recent evidence suggesting that adults with mental health conditions account for half of opioid prescriptions in the USA.[@R30]

A recent study by Frogner *et al* also found that patients with LBP who saw physical therapists initially had lower opioid use, although this study only focused on six states.[@R13] Another recent study by Hayward *et al* evaluated the use of non-opioid treatments from various providers, including physical therapists and physicians, however this was a descriptive study across only 16 states.[@R31] Our study examines the association of conservative therapy on opioid use with a sample that is national in scope. We also provide a broader depiction of conservative therapy, as we included chiropractors and acupuncturists in addition to physical therapists, as well as other MD specialists. Importantly, we find that conservative therapists other than physical therapists, including chiropractors and acupuncturists, when seen first after a new episode of LBP are apparently protective of early and long-term use of opioids when compared with PCPs. Finally, we go beyond investigating the odds of opioid use for a one-time LBP event, by examining associations with both early and long-term opioid use among patients with new-onset LBP, using rigorous definitions of recent onset.

Fritz *et al* found that early PT was associated with decreased opioid prescriptions,[@R32] and a review by Ojha *et al* noted that early PT as treatment for musculoskeletal disorders was associated with decreased frequency of opioid prescriptions, although this was based on a limited number of outcomes.[@R33] Thackerary *et al* also suggested that the odds of receiving an opioid prescription among Medicaid beneficiaries were reduced for those who had a PT consult, as compared with those who did not.[@R34] While these studies did not measure the odds of opioid use among patients who initially saw physical therapists compared with other initial providers, our results are consistent with previously published reports that PT is associated with lower odds of opioid use.

Limitations {#s4-2}
-----------

There are several limitations to this study. Analysis was conducted using claims data, limiting our generalisability beyond commercial and MA enrolled patients. However, the sample is national in scope and provides a range of sociodemographic and clinical characteristics. The observational nature of the study and the use of claims data limited our ability to eliminate the influence of unmeasured confounders. In particular, confounding by indication may bias our results. Patients who seek early treatment with non-pharmacological practitioners may be more likely to have mild back pain that does not require more aggressive treatment such as opioids, compared with individuals with more severe back pain who may be more likely to see practitioners able to prescribe opioids. Studies have suggested that those with more severe LBP are more likely to receive opioids,[@R35] and if patients with less severe pain were more likely to choose conservative therapists rather than physicians, this could contribute to overestimation of the protective effect of conservative therapy on opioid use. Several prior studies have shown comparable baseline pain scores for those who choose conservative therapists compared with those who choose to see physicians initially, however it is important to note that these studies had different patient populations than this study as they were conducted either only in one state or in countries other than the USA.[@R35] Other unmeasured confounders may include patient preferences and behavioural characteristics. For example, those who chose conservative therapists as initial providers for LBP may have preferences to avoid pharmacological and/or opioid therapy. Therefore, while the associations between initial healthcare providers for LBP and subsequent opioid therapy found in our analyses have potentially important implications, one cannot infer causality due to the observational retrospective nature of the study.

Policy implications and future research {#s4-3}
---------------------------------------

In conclusion, our results suggest that use of conservative therapists as initial providers for new-onset LBP are associated with lower odds of early and long-term use of opioids compared with PCPs. Further research in other settings and prospective pragmatic trials will be useful to confirm our findings and to better understand other factors that influence choice of initial providers for LBP. Future research should include personal factors such as preferences related to opioid use, and medical, non-medical and specialists as initial providers. Factors related to health plan benefit design such as out-of-pocket costs for treatment alternatives (eg, PT and chiropractor visits, opioids) and impact of gatekeeper requirements on care patterns should be investigated.
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